Germany's Merck KGaA to Buy Silence Therapeutics for About $1.3 Billion, Adding Rare Blood Cancer Drug
The all-cash deal pays $20 per American depositary share, a 130% premium. Silence's lead drug, divesiran, is being readied for a late-stage trial in polycythemia vera, a rare blood cancer.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Merck KGaA agreed Monday to buy Silence Therapeutics for about $1.3 billion in…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.